Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1594P - SARS-CoV-2 vaccines in cancer patients (pts), real-world data (RWD) from 1069 Belong.life users

Date

16 Sep 2021

Session

ePoster Display

Presenters

Eli Sapir

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

E. Sapir1, N. Moisa2, A. Litvin2, E. Malki2, D.A. Vorobiof2

Author affiliations

  • 1 Radiation Oncology Institute, Assuta Ashdod University Hospital, Ben Gurion University of the Negev, 7747629 - Ashdod/IL
  • 2 Clinical Research, Belongtail Ltd, 6099100 - Bnei Atarot/IL
More

Abstract 1594P

Background

The COVID-19 pandemic continues to have a serious impact on many people, including cancer pts. The US CDC and oncology groups (ASCO, ESMO, ACS) made recommendations as to what high risk groups should be vaccinated first which includes cancer pts. Users of Belong.life, a worldwide, free, and voluntary, digital health application for cancer pts, replied to a targeted survey including demographic & clinical questions related to the pts cancers, ongoing therapies and the Covid 19 vaccination characteristics, and interactions.

Methods

In this prospective study, 1069 cancer pts, Belong.life users, voluntarily replied to a survey asking demographic and clinical questions related to their Covid 19 vaccination and cancer status characteristics.

Results

Most of the pts were North American based (91 %), with 6.3 % from Europe and 2.6% from the rest of the world. 72% were between 50-69 years of age, and 79.5% were females. Five most common diagnosis were Breast Cancer (35.2%), gynecological (14.4%), gastrointestinal (13.3%), lung cancers (9.7%) and genitourinary (7%). 59% of the pts received chemotherapy,14.2% immunotherapy and 32.8% had radiotherapy over the past 12 months prior to receive the Covid 19 vaccination, which consisted of mRNA vaccines in 82.2% (Pfizer 46.2%, Moderna 36%). 4.9% of the pts refused vaccination. 82.3% of the pts had none (39.3%) or mild (43%) side-effects (S/E) and only 2.4% reported severe S/E. Most S/E lasted 1-3 days (89.4%) consisting mainly of sore arm (42.5%), headache (23.3%), fatigue (21.1%), and temperature (18.5%). Swollen lymph-nodes and allergic reactions were only reported in 0.7% (each). 49% of the pts were vaccinated while actively engaged on treatment, and in 96% there was no delay, interruption, or stoppage of the anticancer therapy.

Conclusions

This is the first large report on Real word data voluntarily obtained from 1069 Belong.life users undergoing anticancer treatment with 90% of them receiving a Covid 19 vaccination. The large majority of pts had none or mild S/E (82.3%), and those were short lived (1-3 days in 89.4%) while only in 2% it was graded as severe. In 96% of the pts their ongoing anticancer therapy did not necessitate to be delayed, interrupted, or stopped.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

E. Sapir: Financial Interests, Personal, Advisory Role, Consultant: Belong.life; Financial Interests, Personal, Advisory Role, Consultant: MSD; Financial Interests, Personal, Advisory Role, Consultant: AstraZeneca. N. Moisa: Financial Interests, Personal, Full or part-time Employment: BelongTail. A. Litvin: Financial Interests, Personal, Full or part-time Employment: BelongTail. E. Malki: Financial Interests, Personal, Full or part-time Employment: BelongTail; Financial Interests, Personal, Full or part-time Employment: Belong.life. D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: BelongTail; Financial Interests, Personal, Full or part-time Employment: Belong.life.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings